# A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome

> **NCT03384420** · PHASE1,PHASE2 · COMPLETED · sponsor: **Minovia Therapeutics Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Mitochondrial Diseases
- Pearson Syndrome

## Interventions

- **BIOLOGICAL:** CD34+ cells enriched with MNV-BLD

## Key facts

- **NCT ID:** NCT03384420
- **Lead sponsor:** Minovia Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-13
- **Primary completion:** 2021-03-09
- **Final completion:** 2021-03-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384420, "A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03384420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*